Accuray beats Q4 revenue estimates

Overview

• Accuray fiscal Q4 revenue up 14% yr/yr, beating analyst expectations, per LSEG data

• Fiscal 2025 revenue rises 3% to $458.5 mln, net loss at $1.6 mln

• Co completes debt refinancing, issues FY26 guidance of $471-485 mln revenue

Outlook

• Accuray expects FY26 revenue between $471 mln and $485 mln

• Company forecasts FY26 adjusted EBITDA of $31 mln to $35 mln

• Accuray cites supply chain and economic conditions as potential challenges

Result Drivers

• SERVICE REVENUE GROWTH - Service revenue increased by 4% to $56.8 mln, compared to $54.6 mln in the prior year qtr, contributing positively to the overall performance

• PRODUCT REVENUE DECLINE - Product revenue fell by 11% to $70.7 mln, down from $79.7 mln in the prior year qtr

• GROSS PROFIT IMPROVEMENT - Gross profit margin improved to 30.6% from 28.6% in the prior year qtr, despite a decline in net revenue

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

• Wall Street's median 12-month price target for Accuray Inc is $4.25, about 65.2% above its August 12 closing price of $1.48

Press Release: ID:nPn9znmBFa